{"entity":{"type":"insider","cik":"0001264949","url":"/insider/0001264949","json_url":"/insider/0001264949.json","name":"ZANTE GREG","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":63,"n_filings":20,"first":"2004-10-01","last":"2026-07-29","span_basis":"filed_date"},"name_variants":[{"name":"ZANTE GREG","source":"filing","n_filings":20,"first_seen":"2004-10-01","last_seen":"2026-07-29"}],"transactions":[{"id":6041104,"accession":"0001193125-26-324447","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001193125-26-324447","line_url":"/filing/0001193125-26-324447#line-2","is_derivative":false,"issuer_cik":"0001264949","issuer_name":"Viking Therapeutics, Inc.","issuer_ticker":"VKTX","issuer_name_source":null,"issuer_url":"/issuer/0001264949","owner_cik":"0001264949","owner_name":"ZANTE GREG","owner_display_name":"ZANTE GREG","owner_url":"/insider/0001264949","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock, par value $0.00001 per share","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":21217.0,"shares_display":"21,217","price_per_share":33.4704,"price_display":"33.47","price_state":"stated","total_value":710141.4768,"total_display":"710,141.48","total_whole":"710,141","shares_owned_after":212204.0,"shares_owned_after_display":"212,204","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-07-29","filed_date":"2026-07-29","scope":"insider"},{"id":5943158,"accession":"0001193125-26-003116","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001193125-26-003116","line_url":"/filing/0001193125-26-003116","is_derivative":false,"issuer_cik":"0001264949","issuer_name":"Viking Therapeutics, Inc.","issuer_ticker":"VKTX","issuer_name_source":null,"issuer_url":"/issuer/0001264949","owner_cik":"0001264949","owner_name":"ZANTE GREG","owner_display_name":"ZANTE GREG","owner_url":"/insider/0001264949","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock, par value $0.00001 per share","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":57661.0,"shares_display":"57,661","price_per_share":32.89865567714747,"price_display":"32.90","price_state":"stated","total_value":1896969.385,"total_display":"1,896,969.38","total_whole":"1,896,969","shares_owned_after":215571.0,"shares_owned_after_display":"215,571","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-01-05","filed_date":"2026-01-05","scope":"insider","n_lines":4},{"id":5108105,"accession":"0001193125-25-254298","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001193125-25-254298","line_url":"/filing/0001193125-25-254298#line-2","is_derivative":false,"issuer_cik":"0001264949","issuer_name":"Viking Therapeutics, Inc.","issuer_ticker":"VKTX","issuer_name_source":null,"issuer_url":"/issuer/0001264949","owner_cik":"0001264949","owner_name":"ZANTE GREG","owner_display_name":"ZANTE GREG","owner_url":"/insider/0001264949","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock, par value $0.00001 per share","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6185.0,"shares_display":"6,185","price_per_share":35.0009,"price_display":"35.00","price_state":"stated","total_value":216480.5665,"total_display":"216,480.57","total_whole":"216,481","shares_owned_after":173592.0,"shares_owned_after_display":"173,592","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-10-28","filed_date":"2025-10-28","scope":"insider"},{"id":4063120,"accession":"0000950170-25-093792","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-25-093792","line_url":"/filing/0000950170-25-093792#line-2","is_derivative":false,"issuer_cik":"0001264949","issuer_name":"Viking Therapeutics, Inc.","issuer_ticker":"VKTX","issuer_name_source":null,"issuer_url":"/issuer/0001264949","owner_cik":"0001264949","owner_name":"ZANTE GREG","owner_display_name":"ZANTE GREG","owner_url":"/insider/0001264949","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock, par value $0.00001 per share","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4266.0,"shares_display":"4,266","price_per_share":27.761,"price_display":"27.76","price_state":"stated","total_value":118428.426,"total_display":"118,428.43","total_whole":"118,428","shares_owned_after":168660.0,"shares_owned_after_display":"168,660","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-07-03","filed_date":"2025-07-03","scope":"insider"},{"id":4058949,"accession":"0000950170-25-002485","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000950170-25-002485","line_url":"/filing/0000950170-25-002485","is_derivative":false,"issuer_cik":"0001264949","issuer_name":"Viking Therapeutics, Inc.","issuer_ticker":"VKTX","issuer_name_source":null,"issuer_url":"/issuer/0001264949","owner_cik":"0001264949","owner_name":"ZANTE GREG","owner_display_name":"ZANTE GREG","owner_url":"/insider/0001264949","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock, par value $0.00001 per share","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":50309.0,"shares_display":"50,309","price_per_share":42.74771232185096,"price_display":"42.75","price_state":"stated","total_value":2150594.6592,"total_display":"2,150,594.66","total_whole":"2,150,595","shares_owned_after":169959.0,"shares_owned_after_display":"169,959","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-01-06","filed_date":"2025-01-06","scope":"insider","n_lines":2},{"id":2828677,"accession":"0000950170-24-117885","txn_seq":12,"anchor":"line-12","filing_url":"/filing/0000950170-24-117885","line_url":"/filing/0000950170-24-117885","is_derivative":false,"issuer_cik":"0001264949","issuer_name":"Viking Therapeutics, Inc.","issuer_ticker":"VKTX","issuer_name_source":null,"issuer_url":"/issuer/0001264949","owner_cik":"0001264949","owner_name":"ZANTE GREG","owner_display_name":"ZANTE GREG","owner_url":"/insider/0001264949","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock, par value $0.00001 per share","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":131687.0,"shares_display":"131,687","price_per_share":76.61473083979436,"price_display":"76.61","price_state":"stated","total_value":10089164.0601,"total_display":"10,089,164.06","total_whole":"10,089,164","shares_owned_after":231381.0,"shares_owned_after_display":"231,381","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-10-28","filed_date":"2024-10-28","scope":"insider","n_lines":8},{"id":2985693,"accession":"0000950170-24-088538","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0000950170-24-088538","line_url":"/filing/0000950170-24-088538","is_derivative":false,"issuer_cik":"0001264949","issuer_name":"Viking Therapeutics, Inc.","issuer_ticker":"VKTX","issuer_name_source":null,"issuer_url":"/issuer/0001264949","owner_cik":"0001264949","owner_name":"ZANTE GREG","owner_display_name":"ZANTE GREG","owner_url":"/insider/0001264949","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock, par value $0.00001 per share","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":16136.0,"shares_display":"16,136","price_per_share":57.15245785820525,"price_display":"57.15","price_state":"stated","total_value":922212.06,"total_display":"922,212.06","total_whole":"922,212","shares_owned_after":190526.0,"shares_owned_after_display":"190,526","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-07-30","filed_date":"2024-07-31","scope":"insider","n_lines":3},{"id":2092893,"accession":"0001209191-24-005522","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001209191-24-005522","line_url":"/filing/0001209191-24-005522","is_derivative":false,"issuer_cik":"0001264949","issuer_name":"Viking Therapeutics, Inc.","issuer_ticker":"VKTX","issuer_name_source":null,"issuer_url":"/issuer/0001264949","owner_cik":"0001264949","owner_name":"ZANTE GREG","owner_display_name":"ZANTE GREG","owner_url":"/insider/0001264949","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock, par value $0.00001 per share","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":66756.0,"shares_display":"66,756","price_per_share":74.69003486727784,"price_display":"74.69","price_state":"stated","total_value":4986007.9676,"total_display":"4,986,007.97","total_whole":"4,986,008","shares_owned_after":192939.0,"shares_owned_after_display":"192,939","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-05-03","filed_date":"2024-05-03","scope":"insider","n_lines":4},{"id":2247939,"accession":"0001209191-24-000929","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001209191-24-000929","line_url":"/filing/0001209191-24-000929#line-6","is_derivative":false,"issuer_cik":"0001264949","issuer_name":"Viking Therapeutics, Inc.","issuer_ticker":"VKTX","issuer_name_source":null,"issuer_url":"/issuer/0001264949","owner_cik":"0001264949","owner_name":"ZANTE GREG","owner_display_name":"ZANTE GREG","owner_url":"/insider/0001264949","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock, par value $0.00001 per share","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":15000.0,"shares_display":"15,000","price_per_share":17.9,"price_display":"17.90","price_state":"stated","total_value":268500.0,"total_display":"268,500.00","total_whole":"268,500","shares_owned_after":180730.0,"shares_owned_after_display":"180,730","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-01-04","filed_date":"2024-01-04","scope":"insider"},{"id":8438009,"accession":"0001209191-23-024722","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-23-024722","line_url":"/filing/0001209191-23-024722#line-2","is_derivative":false,"issuer_cik":"0001264949","issuer_name":"Viking Therapeutics, Inc.","issuer_ticker":"VKTX","issuer_name_source":null,"issuer_url":"/issuer/0001264949","owner_cik":"0001264949","owner_name":"ZANTE GREG","owner_display_name":"ZANTE GREG","owner_url":"/insider/0001264949","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock, par value $0.00001 per share","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7500.0,"shares_display":"7,500","price_per_share":20.0,"price_display":"20.00","price_state":"stated","total_value":150000.0,"total_display":"150,000.00","total_whole":"150,000","shares_owned_after":149279.0,"shares_owned_after_display":"149,279","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-04-17","filed_date":"2023-04-18","scope":"insider"},{"id":7918418,"accession":"0001209191-23-024227","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0001209191-23-024227","line_url":"/filing/0001209191-23-024227#line-8","is_derivative":false,"issuer_cik":"0001264949","issuer_name":"Viking Therapeutics, Inc.","issuer_ticker":"VKTX","issuer_name_source":null,"issuer_url":"/issuer/0001264949","owner_cik":"0001264949","owner_name":"ZANTE GREG","owner_display_name":"ZANTE GREG","owner_url":"/insider/0001264949","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock, par value $0.00001 per share","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":41544.0,"shares_display":"41,544","price_per_share":18.0,"price_display":"18.00","price_state":"stated","total_value":747792.0,"total_display":"747,792.00","total_whole":"747,792","shares_owned_after":149279.0,"shares_owned_after_display":"149,279","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-04-12","filed_date":"2023-04-13","scope":"insider"},{"id":7918409,"accession":"0001209191-23-024227","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001209191-23-024227","line_url":"/filing/0001209191-23-024227#line-5","is_derivative":false,"issuer_cik":"0001264949","issuer_name":"Viking Therapeutics, Inc.","issuer_ticker":"VKTX","issuer_name_source":null,"issuer_url":"/issuer/0001264949","owner_cik":"0001264949","owner_name":"ZANTE GREG","owner_display_name":"ZANTE GREG","owner_url":"/insider/0001264949","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock, par value $0.00001 per share","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":56295.0,"shares_display":"56,295","price_per_share":18.0037,"price_display":"18.00","price_state":"stated","total_value":1013518.2915,"total_display":"1,013,518.29","total_whole":"1,013,518","shares_owned_after":149279.0,"shares_owned_after_display":"149,279","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-04-11","filed_date":"2023-04-13","scope":"insider"},{"id":7897437,"accession":"0001209191-23-022398","txn_seq":9,"anchor":"line-9","filing_url":"/filing/0001209191-23-022398","line_url":"/filing/0001209191-23-022398#line-9","is_derivative":false,"issuer_cik":"0001264949","issuer_name":"Viking Therapeutics, Inc.","issuer_ticker":"VKTX","issuer_name_source":null,"issuer_url":"/issuer/0001264949","owner_cik":"0001264949","owner_name":"ZANTE GREG","owner_display_name":"ZANTE GREG","owner_url":"/insider/0001264949","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock, par value $0.00001 per share","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":30911.0,"shares_display":"30,911","price_per_share":18.0,"price_display":"18.00","price_state":"stated","total_value":556398.0,"total_display":"556,398.00","total_whole":"556,398","shares_owned_after":147778.0,"shares_owned_after_display":"147,778","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-04-03","filed_date":"2023-04-03","scope":"insider"},{"id":7897427,"accession":"0001209191-23-022398","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001209191-23-022398","line_url":"/filing/0001209191-23-022398#line-5","is_derivative":false,"issuer_cik":"0001264949","issuer_name":"Viking Therapeutics, Inc.","issuer_ticker":"VKTX","issuer_name_source":null,"issuer_url":"/issuer/0001264949","owner_cik":"0001264949","owner_name":"ZANTE GREG","owner_display_name":"ZANTE GREG","owner_url":"/insider/0001264949","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock, par value $0.00001 per share","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":131029.0,"shares_display":"131,029","price_per_share":17.0025,"price_display":"17.00","price_state":"stated","total_value":2227820.5725,"total_display":"2,227,820.57","total_whole":"2,227,821","shares_owned_after":147778.0,"shares_owned_after_display":"147,778","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-03-30","filed_date":"2023-04-03","scope":"insider"},{"id":4011029,"accession":"0001181431-08-018490","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001181431-08-018490","line_url":"/filing/0001181431-08-018490#line-2","is_derivative":false,"issuer_cik":"0001001233","issuer_name":"SANGAMO BIOSCIENCES INC","issuer_ticker":"SGMO","issuer_name_source":null,"issuer_url":"/issuer/0001001233","owner_cik":"0001264949","owner_name":"ZANTE GREG","owner_display_name":"ZANTE GREG","owner_url":"/insider/0001264949","role":"Officer (VP, Finance & Administration)","role_mark":"O","role_mark_label":"Officer (VP, Finance & Administration)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"VP, Finance & Administration","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":100.0,"shares_display":"100","price_per_share":12.0,"price_display":"12.00","price_state":"stated","total_value":1200.0,"total_display":"1,200.00","total_whole":"1,200","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2008-02-14","filed_date":"2008-03-12","scope":"insider"},{"id":3966518,"accession":"0001209191-08-011500","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-08-011500","line_url":"/filing/0001209191-08-011500","is_derivative":false,"issuer_cik":"0001001233","issuer_name":"SANGAMO BIOSCIENCES INC","issuer_ticker":"SGMO","issuer_name_source":null,"issuer_url":"/issuer/0001001233","owner_cik":"0001264949","owner_name":"ZANTE GREG","owner_display_name":"ZANTE GREG","owner_url":"/insider/0001264949","role":"Officer (Vice President, Fin. & Admin)","role_mark":"O","role_mark_label":"Officer (Vice President, Fin. & Admin)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Vice President, Fin. & Admin.","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5000.0,"shares_display":"5,000","price_per_share":12.019,"price_display":"12.02","price_state":"stated","total_value":60095.0,"total_display":"60,095.00","total_whole":"60,095","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2008-02-14","filed_date":"2008-02-19","scope":"insider","n_lines":2},{"id":2462270,"accession":"0001209191-08-003149","txn_seq":13,"anchor":"line-13","filing_url":"/filing/0001209191-08-003149","line_url":"/filing/0001209191-08-003149","is_derivative":false,"issuer_cik":"0001001233","issuer_name":"SANGAMO BIOSCIENCES INC","issuer_ticker":"SGMO","issuer_name_source":null,"issuer_url":"/issuer/0001001233","owner_cik":"0001264949","owner_name":"ZANTE GREG","owner_display_name":"ZANTE GREG","owner_url":"/insider/0001264949","role":"Officer (Vice President, Fin. & Admin)","role_mark":"O","role_mark_label":"Officer (Vice President, Fin. & Admin)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Vice President, Fin. & Admin.","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5000.0,"shares_display":"5,000","price_per_share":12.874,"price_display":"12.87","price_state":"stated","total_value":64370.0,"total_display":"64,370.00","total_whole":"64,370","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2008-01-08","filed_date":"2008-01-10","scope":"insider","n_lines":10},{"id":6927504,"accession":"0001209191-07-069168","txn_seq":13,"anchor":"line-13","filing_url":"/filing/0001209191-07-069168","line_url":"/filing/0001209191-07-069168#line-13","is_derivative":false,"issuer_cik":"0001001233","issuer_name":"SANGAMO BIOSCIENCES INC","issuer_ticker":"SGMO","issuer_name_source":null,"issuer_url":"/issuer/0001001233","owner_cik":"0001264949","owner_name":"ZANTE GREG","owner_display_name":"ZANTE GREG","owner_url":"/insider/0001264949","role":"Officer (Vice President, Fin. & Admin)","role_mark":"O","role_mark_label":"Officer (Vice President, Fin. & Admin)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Vice President, Fin. & Admin.","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1900.0,"shares_display":"1,900","price_per_share":15.97,"price_display":"15.97","price_state":"stated","total_value":30343.0,"total_display":"30,343.00","total_whole":"30,343","shares_owned_after":100.0,"shares_owned_after_display":"100","ownership_form":"D","is_10b5_1":null,"transaction_date":"2007-12-07","filed_date":"2007-12-11","scope":"insider"},{"id":6927501,"accession":"0001209191-07-069168","txn_seq":12,"anchor":"line-12","filing_url":"/filing/0001209191-07-069168","line_url":"/filing/0001209191-07-069168#line-12","is_derivative":false,"issuer_cik":"0001001233","issuer_name":"SANGAMO BIOSCIENCES INC","issuer_ticker":"SGMO","issuer_name_source":null,"issuer_url":"/issuer/0001001233","owner_cik":"0001264949","owner_name":"ZANTE GREG","owner_display_name":"ZANTE GREG","owner_url":"/insider/0001264949","role":"Officer (Vice President, Fin. & Admin)","role_mark":"O","role_mark_label":"Officer (Vice President, Fin. & Admin)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Vice President, Fin. & Admin.","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":900.0,"shares_display":"900","price_per_share":15.68,"price_display":"15.68","price_state":"stated","total_value":14112.0,"total_display":"14,112.00","total_whole":"14,112","shares_owned_after":2450.0,"shares_owned_after_display":"2,450","ownership_form":"D","is_10b5_1":null,"transaction_date":"2007-12-07","filed_date":"2007-12-11","scope":"insider"},{"id":6927498,"accession":"0001209191-07-069168","txn_seq":11,"anchor":"line-11","filing_url":"/filing/0001209191-07-069168","line_url":"/filing/0001209191-07-069168#line-11","is_derivative":false,"issuer_cik":"0001001233","issuer_name":"SANGAMO BIOSCIENCES INC","issuer_ticker":"SGMO","issuer_name_source":null,"issuer_url":"/issuer/0001001233","owner_cik":"0001264949","owner_name":"ZANTE GREG","owner_display_name":"ZANTE GREG","owner_url":"/insider/0001264949","role":"Officer (Vice President, Fin. & Admin)","role_mark":"O","role_mark_label":"Officer (Vice President, Fin. & Admin)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Vice President, Fin. & Admin.","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":800.0,"shares_display":"800","price_per_share":15.59,"price_display":"15.59","price_state":"stated","total_value":12472.0,"total_display":"12,472.00","total_whole":"12,472","shares_owned_after":3750.0,"shares_owned_after_display":"3,750","ownership_form":"D","is_10b5_1":null,"transaction_date":"2007-12-07","filed_date":"2007-12-11","scope":"insider"},{"id":6927495,"accession":"0001209191-07-069168","txn_seq":10,"anchor":"line-10","filing_url":"/filing/0001209191-07-069168","line_url":"/filing/0001209191-07-069168#line-10","is_derivative":false,"issuer_cik":"0001001233","issuer_name":"SANGAMO BIOSCIENCES INC","issuer_ticker":"SGMO","issuer_name_source":null,"issuer_url":"/issuer/0001001233","owner_cik":"0001264949","owner_name":"ZANTE GREG","owner_display_name":"ZANTE GREG","owner_url":"/insider/0001264949","role":"Officer (Vice President, Fin. & Admin)","role_mark":"O","role_mark_label":"Officer (Vice President, Fin. & Admin)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Vice President, Fin. & Admin.","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":400.0,"shares_display":"400","price_per_share":15.98,"price_display":"15.98","price_state":"stated","total_value":6392.0,"total_display":"6,392.00","total_whole":"6,392","shares_owned_after":3350.0,"shares_owned_after_display":"3,350","ownership_form":"D","is_10b5_1":null,"transaction_date":"2007-12-07","filed_date":"2007-12-11","scope":"insider"},{"id":6927492,"accession":"0001209191-07-069168","txn_seq":9,"anchor":"line-9","filing_url":"/filing/0001209191-07-069168","line_url":"/filing/0001209191-07-069168#line-9","is_derivative":false,"issuer_cik":"0001001233","issuer_name":"SANGAMO BIOSCIENCES INC","issuer_ticker":"SGMO","issuer_name_source":null,"issuer_url":"/issuer/0001001233","owner_cik":"0001264949","owner_name":"ZANTE GREG","owner_display_name":"ZANTE GREG","owner_url":"/insider/0001264949","role":"Officer (Vice President, Fin. & Admin)","role_mark":"O","role_mark_label":"Officer (Vice President, Fin. & Admin)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Vice President, Fin. & Admin.","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":249.0,"shares_display":"249","price_per_share":15.53,"price_display":"15.53","price_state":"stated","total_value":3866.97,"total_display":"3,866.97","total_whole":"3,867","shares_owned_after":4751.0,"shares_owned_after_display":"4,751","ownership_form":"D","is_10b5_1":null,"transaction_date":"2007-12-07","filed_date":"2007-12-11","scope":"insider"},{"id":6927489,"accession":"0001209191-07-069168","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0001209191-07-069168","line_url":"/filing/0001209191-07-069168#line-8","is_derivative":false,"issuer_cik":"0001001233","issuer_name":"SANGAMO BIOSCIENCES INC","issuer_ticker":"SGMO","issuer_name_source":null,"issuer_url":"/issuer/0001001233","owner_cik":"0001264949","owner_name":"ZANTE GREG","owner_display_name":"ZANTE GREG","owner_url":"/insider/0001264949","role":"Officer (Vice President, Fin. & Admin)","role_mark":"O","role_mark_label":"Officer (Vice President, Fin. & Admin)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Vice President, Fin. & Admin.","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":200.0,"shares_display":"200","price_per_share":15.69,"price_display":"15.69","price_state":"stated","total_value":3138.0,"total_display":"3,138.00","total_whole":"3,138","shares_owned_after":2250.0,"shares_owned_after_display":"2,250","ownership_form":"D","is_10b5_1":null,"transaction_date":"2007-12-07","filed_date":"2007-12-11","scope":"insider"},{"id":6927486,"accession":"0001209191-07-069168","txn_seq":7,"anchor":"line-7","filing_url":"/filing/0001209191-07-069168","line_url":"/filing/0001209191-07-069168#line-7","is_derivative":false,"issuer_cik":"0001001233","issuer_name":"SANGAMO BIOSCIENCES INC","issuer_ticker":"SGMO","issuer_name_source":null,"issuer_url":"/issuer/0001001233","owner_cik":"0001264949","owner_name":"ZANTE GREG","owner_display_name":"ZANTE GREG","owner_url":"/insider/0001264949","role":"Officer (Vice President, Fin. & Admin)","role_mark":"O","role_mark_label":"Officer (Vice President, Fin. & Admin)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Vice President, Fin. & Admin.","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":150.0,"shares_display":"150","price_per_share":15.8,"price_display":"15.80","price_state":"stated","total_value":2370.0,"total_display":"2,370.00","total_whole":"2,370","shares_owned_after":2000.0,"shares_owned_after_display":"2,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2007-12-07","filed_date":"2007-12-11","scope":"insider"}],"collapsed":true,"next_cursor":"2007-12-07|6927486","ledger_fault":false,"count":{"value":63,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":63,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":63},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001607678","name":"Viking Therapeutics, Inc.","url":"/issuer/0001607678","role":"Officer (Chief Financial Officer)","n_filings":12,"first_seen":"2023-04-03","last_seen":"2026-07-29"},{"type":"issuer","type_label":"ISSUER","cik":"0001001233","name":"SANGAMO BIOSCIENCES INC","url":"/issuer/0001001233","role":"Officer (VP, Finance & Administration)","n_filings":8,"first_seen":"2004-10-01","last_seen":"2008-03-12"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001264949","retrieved_at":"2026-08-25T10:07:34+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-24","last_ingest":"2026-08-25T05:24:19.374141+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}